Orgenesis (ORGS) Competitors

Iterum Therapeutics (NASDAQ:ITRM) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Which has higher valuation & earnings, ITRM or ORGS?

Iterum Therapeutics has higher earnings, but lower revenue than Orgenesis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	N/A	N/A	-$24.77M	-$1.31	-0.85
Orgenesis	$662K	16.44	-$55.36M	N/A	N/A

Does the media prefer ITRM or ORGS?

In the previous week, Iterum Therapeutics had 4 more articles in the media than Orgenesis. MarketBeat recorded 5 mentions for Iterum Therapeutics and 1 mentions for Orgenesis. Iterum Therapeutics' average media sentiment score of 1.22 beat Orgenesis' score of 0.00 indicating that Iterum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iterum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orgenesis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer ITRM or ORGS?

Iterum Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 346.43%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Iterum Therapeutics is more favorable than Orgenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more risk & volatility, ITRM or ORGS?

Iterum Therapeutics has a beta of 2.87, meaning that its stock price is 187% more volatile than the S&P 500. Comparatively, Orgenesis has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Do insiders & institutionals believe in ITRM or ORGS?

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 9.2% of Iterum Therapeutics shares are held by company insiders. Comparatively, 5.7% of Orgenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community favor ITRM or ORGS?

Iterum Therapeutics received 140 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 62.95% of users gave Iterum Therapeutics an outperform vote.

Company	Underperform	Outperform
Iterum Therapeutics	Outperform Votes 141 62.95%	Underperform Votes 83 37.05%
Orgenesis	Outperform Votes 1 100.00%	Underperform Votes No Votes

Is ITRM or ORGS more profitable?

Iterum Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-90.85%
Orgenesis	-3,827.81%	N/A	-130.18%

Summary

Iterum Therapeutics beats Orgenesis on 11 of the 14 factors compared between the two stocks.